Elaia_Partners

🙊 They did it again: a year after their Series D, Mirakl raises $555m led by Silver Lake with participation from long-term investors 83NORTH, Felix Capital & Permira at a $3.5B valuation to power accelerated growth of world’s leading enterprises through online marketplaces! 💥

This breathtaking round will allow them to:
🔬 Hire 350 engineers by 2023
📈 Double their customer success organization
✨ Expand the size of Mirakl Connect
🌎 Expand their geographic reach

👏 We’ve been blown away by Philippe Corrot, Adrien Nussenbaum, Nagi Letaifa, Brian Callahan, Brendan Walsh, Joe Sawyer, Isabelle Bénard, Andy Barker, Sophie Marchessou, Marc Teulières & their amazing team!

🤩For us, it’s a fantastic proof point of our invest-early-in-tech-champions strategy, with a price per share now close to 300 times higher than the one we initially paid in 2012.

🦄 By reading these outstanding numbers, you are probably wondering: How will the founders and managers keep on growing Mirakl’s valuation from now on? What is next? Xavier Lazarus wrote about what we believe is next for Mirakl and why we are still backing a 10 year old business at $3.5B

https://medium.com/elaia/why-are-we-still-backing-mirakl-at-a-3-5b-77ba9106c423

What did 2020 mean for Elaia? 🔍
💵 Returning more money to our LPs than we invested in startups.
🤝 13 new companies joined the in 2020 from pre-seed to Series B in FinTech
👋 3 (almost 4) exits
🏢 (And a new office, take a peak at the end of the article)

Here is a breakdown of our deals, portfolio and exits. We dig deep into the patterns and rationales behind these elements.
La French Tech

Elaia’s 2020 year in review & the sunny road ahead The chaos of 2020 affected everyone but not in the same way. That holds true for venture capital. At Elaia, we had to adapt the way we…

Deep Dive into "Is non-core core?" and why we invest in
⛽️ Discover how startups are the fuel to the transformation engine
🤓 Become an expert in (just) 16 min read!
💸 Understand what is at stake!
🤩 Learn more about our amazing portfolio Fretlink Hyperlex Tinyclues talent.io EASYRECRUE & Holded

Is non-core the new core? Why we invest in digital transformation What are the next hot topics as an investor? This multi-billion dollar question is on everybody’s lips. Our crystal ball at Elaia is no…

🥁 The Holded is on a mission to disrupt small business management with an easy-to-use ERP for SMBs to streamline their financial & operational processes. And we are thrilled to welcome them to the !
Learn more in TechCrunch with MikeButcher about how amazing they are:
👉 €15M Series B funding
👉 80,000 users
👉 70 people (and actively hiring)

Holded, an ‘ERP for small businesses’, raised €15M from Elaia, Lakestar, Nauta and Seedrocket – TechCrunch Holded, a platform billing itself as an ERP aimed at small businesses, has raised a €15M Series B funding round led by VC firm Elaia, together with Lakestar, Nauta Capital and Seedrocket. Holded says it gives small business access to ERP-style planning across invoicing, accounting, sales, project ...

🥁 Une autre IPO pour une start !
👉 Pherecydes Pharma répond à un enjeu de santé majeur: l'antibiorésistance qui pourrait être responsable de 10 millions de décès par an en 2050. Découvrez l'ambition de Guy-Charles Fanneau de La Horie & Philippe Rousseau dans
🎥 Boursorama (à partir de 13min) : https://lnkd.in/dXZSYRW
🗞 Les Echos 👇 : https://lnkd.in/dg73p6n
Euronext France S.A.S.

Pherecydes Pharma entre en Bourse pour combattre l'antibiorésistance La société de biotechnologies nantaise Pherecydes Pharma veut lever entre 7 et 8 millions d'euros sur Euronext Growth, pour mener les essais cliniques de ses virus tueurs de bactéries résistantes, dont le staphylocoque doré. Ses actionnaires actuels s'engagent à soutenir l'IPO à hauteur de 2,...

🥁 Elaia ranks #24 out of 40.000 VC funds active in 🇪🇺

w/ 2 present unicorns & 2 future unicorns according to Dealroom.co in their preliminary report.

👉 Can you guess who are the 2 soonicorns? La French Tech

Launching the 2021 Venture Capital Investor Prominence Rank We’re excited to soft launch the fourth edition of our annual Venture Capital Investor Prominence rank. Every year Dealroom releases a quantitative ranking of Europe’s most prominent venture capital investors. It’s based primarily on the number of unicorns and future unicorns backed by investo...

Flashback to our Cash 💸 in Cloud ☁️ event with as special guest Sébastien MAROTTE, VP Channels EMEA Google Cloud
🤓 Within 20min, become a cloud infra expert!
🙏 Special thanks to Franck Zerbib, Marc Rougier & Gabriel Levy
👉

Cash 💸 in Cloud ☁️

Elaia n°❺ dans le palmarès des VC 🇫🇷 avec 15 deals en France vs. 21 au total en 2020! Ravis d'être aux côtés de Kima Ventures Idinvest Partners, Founders Future & BNP Paris Développement ! Merci Eldorado.co 🙏

Bilan annuel du financement 2020 Retour sur les chiffres, les tendances et les opportunités qui ont marqué l'année 2020.

🥁 Super proud to have been part of this awesome adventure: from Acorus Networks to Volterra to a $500M exit by F5 !
🥳 Congrats & thank you Ankur Singla, Raphael Maunier & Benjamin Schilz !
📍 Marc Rougier shares the key steps & learnings of this amazing journey 👇

A great exit in Elaia portfolio’s: F5 acquires Volterra, the platform for distributed cloud… (aka the amazing story of Acorus Networks)

🥂❄️ 💫 The entire Elaia team wishes you all a magical start to 2021! 🥂❄️ 💫
👉

The entire Elaia team wishes you all a magical start to 2021! 🥂💫

La Aqemia qui a séduit Sanofi est dans Les Echos👇

Aqemia, la deep tech qui a séduit Sanofi Pfizer & BioNTech, AstraZeneca, Moderna : dès l'apparition du Covid-19 , les grands laboratoires pharmaceutiques se sont lancés à toute allure...

🥁 Super proud of Maximilien Levesque & Emmanuelle Martiano Rolland, cofounders of Aqemia who received support and R&D funding from Sanofi to apply their disruptive technology to the discovery of effective treatments for .
More info in Maddyness 👇

Covid-19 : la startup Aqemia sur les rangs pour trouver un médicament La startup Aqemia, spécialisée dans la recherche de médicaments, coopèere avec Sanofi, pour mettre au point un traitement contre le Covid-19.